Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Moodys
Boehringer Ingelheim
Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Hypericin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Hypericin: Patents, clinical trial progress, indications

Hypericin is an investigational drug.

There have been 5 clinical trials for Hypericin. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are HIV Infections, Hepatitis C, and Carcinoma. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), VIMRx Pharmaceuticals, and University Hospital Tuebingen.

There is one US patent protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for Hypericin
TitleSponsorPhase
Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal CarcinosisUniversity Hospital TuebingenPhase 3
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)SoligenixPhase 3
Boceprevir and Ucalm (St John&Apos;s Wort)University of LiverpoolPhase 1

See all Hypericin clinical trials

Clinical Trial Summary for Hypericin

Top disease conditions for Hypericin
Top clinical trial sponsors for Hypericin

See all Hypericin clinical trials

US Patents for Hypericin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Hypericin   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Hypericin   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
Hypericin   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Hypericin   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
Hypericin   Start Trial Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Hypericin

Drugname Country Document Number Estimated Expiration Related US Patent
Hypericin World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Hypericin Australia 2011210567 2030-01-29   Start Trial
Hypericin Canada 2787784 2030-01-29   Start Trial
Hypericin European Patent Office 2528893 2030-01-29   Start Trial
Hypericin European Patent Office 3138838 2030-01-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Harvard Business School
Dow
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.